** Exact Sciences EXAS.O falls 10% to $42.20 after blood colorectal cancer $(CRC)$ test did not meet expectations in trial
** Brokerage BTIG calls it a "worst case scenario"
** This also overshadowed a strong beat and raise Q2
** EXAS on Weds inked deal for exclusive rights to Freenome's blood-based screening CRC test, but analysts noted this excluded multi-cancer tests, which disappointed investors
** At least six brokerages cut price targets
** Shares of rival Guardant Health GH.O gain nearly 17%
** Canaccord Genuity says GH's Shield test performance is a touch better than Freenome's test
** EXAS stock down 27% YTD while GH has surged nearly 70%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。